Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
$34.50
-1.8%		$31.96
$7.45
▼
$42.14
$907.77M-0.28302,324 shs2.20 million shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$18.99
+3.3%		$15.85
$7.78
▼
$34.10
$269.93M1.47116,367 shs302,252 shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$3.10
$3.50
$2.61
▼
$6.55
$928.02M2.123.15 million shs7.41 million shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$8.91
+0.5%		$9.03
$3.79
▼
$11.45
$951.09M2.44916,339 shs4.09 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
-1.79%-7.85%+4.20%+93.60%+3,449,999,900.00%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
+3.26%+22.91%+9.52%-18.78%+70.31%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
0.00%-0.96%-24.39%-1.59%+1.97%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
+0.45%+2.41%-8.52%+6.96%+62.89%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
$34.50
-1.8%		$31.96
$7.45
▼
$42.14
$907.77M-0.28302,324 shs2.20 million shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$18.99
+3.3%		$15.85
$7.78
▼
$34.10
$269.93M1.47116,367 shs302,252 shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$3.10
$3.50
$2.61
▼
$6.55
$928.02M2.123.15 million shs7.41 million shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$8.91
+0.5%		$9.03
$3.79
▼
$11.45
$951.09M2.44916,339 shs4.09 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
-1.79%-7.85%+4.20%+93.60%+3,449,999,900.00%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
+3.26%+22.91%+9.52%-18.78%+70.31%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
0.00%-0.96%-24.39%-1.59%+1.97%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
+0.45%+2.41%-8.52%+6.96%+62.89%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
2.93
Moderate Buy$56.2563.04% Upside
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
2.00
Hold$69.00263.35% Upside
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
2.80
Moderate Buy$9.33201.08% Upside
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
2.85
Moderate Buy$18.69109.79% Upside

Current Analyst Ratings Breakdown

Latest GLSI, FTH, SANA, and SLDB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2026
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$18.00
9/16/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$70.00
9/16/2026
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$18.00
9/15/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/14/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/14/2026
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Loop Capital logo
Loop Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$25.00
9/14/2026
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$25.00
9/9/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
8/27/2026
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$16.00 ➝ $26.00
8/24/2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/21/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$56.00
(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
N/AN/AN/AN/A$14.74 per shareN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.03 per shareN/A
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/A$0.60 per shareN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/A$2.28 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
-$21.08M-$141.65N/AN/AN/AN/A-1,012.17%-175.69%N/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$19.36M-$1.54N/AN/AN/AN/A-793.81%-295.32%11/13/2026 (Estimated)
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$244.17M-$0.76N/AN/AN/AN/A-103.02%-39.16%11/5/2026 (Estimated)
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$174.32M-$1.91N/AN/AN/AN/A-71.35%-60.58%11/2/2026 (Estimated)

Latest GLSI, FTH, SANA, and SLDB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.33-$0.27+$0.06-$0.27N/AN/A
8/10/2026Q2 2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$0.1469-$0.13+$0.0169-$0.22N/AN/A
8/6/2026Q2 2026
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.4624-$0.38+$0.0824-$0.38N/AN/A
8/4/2026Q2 2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
-$5.0450-$2.84+$2.2050-$0.62N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
N/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
N/A
19.69
19.69
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
1.54
1.54
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/A
1.38
1.38
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/A
13.82
13.82

Institutional Ownership

CompanyInstitutional Ownership
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
10.50%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
88.23%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
81.46%

Insider Ownership

CompanyInsider Ownership
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
7.00%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
51.47%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
25.40%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
2.66%
CompanyEmployeesShares OutstandingFree FloatOptionable
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
2925.84 million24.03 millionNot Optionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
1314.68 million7.12 millionNot Optionable
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
142299.36 million223.32 millionOptionable
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
121107.22 million104.37 millionOptionable

Recent News About These Companies

Solid Biosciences (NASDAQ:SLDB) Earns Outperform Rating from Analysts at Royal Bank Of Canada
September 19 at 2:38 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31032215
Solid Biosciences (NASDAQ:SLDB) Upgraded to Moderate Buy at Royal Bank Of Canada
September 17 at 7:41 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-solid-biosciences-nasdaq-sldb-upgraded-to-moderate-buy-at-royal-bank-of-canada-2026-09-17/
RBC Capital initiates coverage of Solid Biosciences at outperform
September 17 at 5:29 AM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/rbc-capital-initiates-coverage-of-solid-biosciences-at-outperform/ar-AA2coj9z
Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC Says
September 16 at 5:52 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/solid-biosciences-apos-duchenne-muscular-151612527.html
Solid Biosciences wins new Outperform at RBC on DMD opportunity
September 16 at 5:52 PM  |  seekingalpha.comhttps://seekingalpha.com/news/4643449-solid-biosciences-wins-new-outperform-rbc
Solid Biosciences (NASDAQ:SLDB) Shares Down 6.4% - Time to Sell?
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-solid-biosciences-nasdaq-sldb-shares-down-64-time-to-sell-2026-09-15/
Solid Biosciences (NASDAQ:SLDB) Earns "Buy" Rating from HC Wainwright
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-solid-biosciences-nasdaq-sldb-earns-buy-rating-from-hc-wainwright-2026-09-14/
Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of "Moderate Buy" by Analysts
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-solid-biosciences-inc-nasdaq-sldb-given-consensus-rating-of-moderate-buy-by-analysts-2026-09-14/
Solid Biosciences (SLDB) Gets a Buy from Citi
September 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4571495/solid-biosciences-sldb-gets-a-buy-from-citi/
Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945256-solid-biosciences-inc-sldb-presents-at-citigroups-biopharma-back-to-school-summit-2026
243,154 Shares in Solid Biosciences Inc. $SLDB Purchased by Bank of New York Mellon Corp
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-243154-shares-in-solid-biosciences-inc-sldb-purchased-by-bank-of-new-york-mellon-corp-2026-09-08/
Solid Biosciences to Participate at Upcoming Investor Conferences
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355087/0/en/solid-biosciences-to-participate-at-upcoming-investor-conferences.html
Solid Biosciences (NASDAQ:SLDB) Price Target Raised to $26.00 at Cantor Fitzgerald
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-solid-biosciences-nasdaq-sldb-price-target-raised-to-2600-at-cantor-fitzgerald-2026-08-27/
Solid Biosciences (NASDAQ:SLDB) Trading 5.5% Higher - Should You Buy?
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-solid-biosciences-nasdaq-sldb-trading-55-higher-should-you-buy-2026-08-25/
Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from Analysts at Truist Financial
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/solid-biosciences-nasdaqsldb-earns-buy-rating-from-analysts-at-truist-financial-2026-08-21/
Solid Biosciences (NASDAQ:SLDB) Stock Price Down 6.7% - Time to Sell?
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/solid-biosciences-nasdaqsldb-stock-price-down-67-time-to-sell-2026-08-20/
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/solid-biosciences-inc-nasdaqsldb-receives-consensus-recommendation-of-moderate-buy-from-brokerages-2026-08-20/
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Solid Biosciences (SLDB)
August 8, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SLDB-Q/pressreleases/3732880/analysts-offer-insights-on-healthcare-companies-cvrx-cvrx-and-solid-biosciences-sldb/
Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/solid-biosciences-reports-second-quarter-200800475.html
Analysts Conflicted on These Healthcare Names: Nuvalent (NUVL) and Solid Biosciences (SLDB)
July 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NUVL/pressreleases/3154852/analysts-conflicted-on-these-healthcare-names-nuvalent-nuvl-and-solid-biosciences-sldb/
Solid Biosciences: The Bull Case Is No Longer Just Duchenne
July 2, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4919335-solid-biosciences-stock-bull-case-no-longer-just-duchenne

New MarketBeat Followers Over Time

Media Sentiment Over Time

Sensei Biotherapeutics stock logo

Sensei Biotherapeutics NASDAQ:FTH

$34.50 -0.63 (-1.79%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$34.48 -0.02 (-0.06%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$18.99 +0.60 (+3.26%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$19.10 +0.11 (+0.60%)
As of 09/18/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Sana Biotechnology stock logo

Sana Biotechnology NASDAQ:SANA

$3.10 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$3.09 -0.01 (-0.32%)
As of 09/18/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Solid Biosciences stock logo

Solid Biosciences NASDAQ:SLDB

$8.91 +0.04 (+0.45%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$8.96 +0.05 (+0.62%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas